



## Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 29, 2025

FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June.

### **Jefferies Global Healthcare Conference**

Format: Fireside Chat

Date and Time: Thursday, June 5, 2025 at 11:05 a.m ET

Location: New York City

### **Goldman Sachs 46<sup>th</sup> Annual Global Healthcare Conference**

Format: Fireside Chat

Date and Time: Monday, June 9, 2025 at 4:00 p.m. ET

Location: Miami

Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at <http://ir.ternspharma.com>. A replay of the webcasts will be archived on Terns' website for at least 30 days following the presentations.

### **About Terns Pharmaceuticals**

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR- $\beta$  agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: [www.ternspharma.com](http://www.ternspharma.com).

### **Contacts for Terns**

#### **Investors**

Kaytee Bock Zafereo

[investors@ternspharma.com](mailto:investors@ternspharma.com)

#### **Media**

Jenna Urban

CG Life

[media@ternspharma.com](mailto:media@ternspharma.com)